Abstract

The present invention proposes use of the RAGE (Receptor for Advanced Glycation End-Products) nuclear protein as a biomarker in an in vitro method for evaluating, determining or predicting the sensitivity or response to treatment with radiological therapy (radiotherapy) and/or radiomimetic drug therapy (chemotherapy), in other words therapy that generates cleavage of the DNA double chain in a tumour patient. The RAGE protein can be used as a lone biomarker or in combination with other biomarkers.